<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202278</url>
  </required_header>
  <id_info>
    <org_study_id>139EK1</org_study_id>
    <nct_id>NCT02202278</nct_id>
  </id_info>
  <brief_title>Study of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation Patients</brief_title>
  <official_title>Serum Levels of IMA, TAC, TOS, OSI and MDA in Severe OHSS Patients Underwent Long Agonist Protocol Intracytoplasmic Sperm for Determining Oxidative Stress Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karadeniz Technical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karadeniz Technical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine serum oxidative stress status by ischemia modified
      albumin (IMA), total antioxidant capacity (TAC), total oxidative capacity (TOS), oxidative
      stress capacity (OSI), and serum malondialdehyde (MDA) in patients with OHHS and control
      group. We also aim to reveal the association between serum levels of these factors and oocyte
      quality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients included in this study were assisted reproductive technique (ART) patients with
           moderate and severe OHSS who were hospitalized for management

        -  Control patients are selected from patients without signs of OHSS

        -  All patients are administered luteal long protocol for controlled ovarian stimulation.
           Pituitary down-regulation with SC injection of GnRH agonist (GnRH-a) (1 mg/day; Lucrin,
           Abbott Laboratories, North Chicago, IL) that was started on day 21 of the previous
           menstrual cycle. Subcutaneous administration of recombinant hFSH (Gonal-F, Laboratories
           Serono S.A., Aubonne, Switzerland) at dosages from 150-225 IU/day is initiated on the
           second or third day of menstruation.

        -  When there are at least two or three follicles &gt;17 mm in diameter, recombinant human
           chorionic gonadotropin (0.25 µgr ; Ovitrelle IM, Serono, Istanbul, Turkey) is applied
           subcutaneously 34-36 hours before oocyte retrieval.

        -  Serum samples are collected on day of HCG for study and control group patients.

        -  Serum levels of ischemia modified albumin (IMA), malondialdehyde (MDA), total oxidative
           capacity (TOS), total antioxidative capacity (TAS) and oxidative stress capacity (OSI)
           levels.

        -  This is a case control study

        -  Statistical analyses will be performed using student t-test and fisher chi-square test.
           The correlations between the serums IMA, TAC, TOC, OSI, and MDA levels will be examined
           in all study groups using Spearman correlation analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change the levels of oxidative stress markers</measure>
    <time_frame>1 day</time_frame>
    <description>Serum will be obtained for studiying ischemia modified albumin (IMA), malondialdehyde (MDA), total oxidative capacity (TOS), total antioxidative capacity (TAS) and oxidative stress capacity (OSI) levels</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>ovarian hyperstimulation patients</arm_group_label>
    <description>Moderate OHSS is defined as abdominal distension and discomfort, nausea with or without vomiting, ovarian enlargement (ovarian size of 8-12 cm) and ascites that revealed by ultrasonografic examination. Severe OHSS criteria is defined as ovarian enlargement, ascites with or without hydrothorax, haematocrit &gt;45%, weight gain &gt;2 kg, white blood cell count &gt;15.000, oliguria, creatinine of 1.0-1.5, creatinine clearance of &gt;50 ml/min, liver dysfunction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without ovarian hiperstimulation</arm_group_label>
    <description>Control group is composed of patients who underwent long luteal protocol but do not demonstrate symptoms of OHSS</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood of involved patients in study was drawn for study for ischemia modified albumin (IMA),
      malondialdehyde (MDA), total oxidative capacity (TOS), total antioxidative capacity (TAS) and
      oxidative stress capacity (OSI) levels. After the study all blood samples will be destroyed
      according to regulations.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that are administered luteal long protocol for controlled ovarian stimulation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Patients in both groups are normoresponders or hyperresponders who will undergo assisted
        reproductive technology for male factor

        Exclusion Criteria:

          -  known inherited or acquired thrombophilia

          -  previous thromboembolism

          -  previous, current or planned anti-thrombotic treatment

          -  first degree relatives with known genetic thrombophilia

          -  systemic diseases

          -  smoking.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>emine seda guvendag guven, MD</last_name>
    <role>Study Director</role>
    <affiliation>Karadeniz Technical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>rafet duraker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>T. C Etlik Zubeyde Hanim Women's health Teaching Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>emine seda guvendag guven, MD</last_name>
    <phone>905332339854</phone>
    <email>emineseda@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>suleyman guven, MD</last_name>
    <phone>90</phone>
    <email>drsuleymanguven@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>T.C Saglik Bakanligi Etlik Zübeyde Hanim Womens Health Teaching Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06600</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>rafet duraker, MD</last_name>
      <phone>905342325333</phone>
      <email>rafetduraker@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>yeşim bayoglu tekin, MD</last_name>
      <phone>05055171973</phone>
      <email>yesimbay@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Serdar Dilbaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmet Mentese, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sevim Aydin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Hitkari JA, Rowe TP, von Dadelszen P. Activated protein C and the ovarian hyperstimulation syndrome: possible therapeutic implications. Med Hypotheses. 2006;66(5):929-33. Epub 2006 Jan 24. Review.</citation>
    <PMID>16434147</PMID>
  </reference>
  <reference>
    <citation>Westerlund E, Henriksson P, Wallén H, Hovatta O, Wallberg KR, Antovic A. Detection of a procoagulable state during controlled ovarian hyperstimulation for in vitro fertilization with global assays of haemostasis. Thromb Res. 2012 Oct;130(4):649-53. doi: 10.1016/j.thromres.2011.11.024. Epub 2011 Dec 7.</citation>
    <PMID>22154245</PMID>
  </reference>
  <reference>
    <citation>Agarwal A, Allamaneni SS. Role of free radicals in female reproductive diseases and assisted reproduction. Reprod Biomed Online. 2004 Sep;9(3):338-47. Review.</citation>
    <PMID>15353087</PMID>
  </reference>
  <reference>
    <citation>Velthut A, Zilmer M, Zilmer K, Kaart T, Karro H, Salumets A. Elevated blood plasma antioxidant status is favourable for achieving IVF/ICSI pregnancy. Reprod Biomed Online. 2013 Apr;26(4):345-52. doi: 10.1016/j.rbmo.2012.12.012. Epub 2013 Jan 16.</citation>
    <PMID>23415995</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karadeniz Technical University</investigator_affiliation>
    <investigator_full_name>emine seda guvendag guven</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <keyword>ovarian hyperstimulation</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>IMA</keyword>
  <keyword>OHSS</keyword>
  <keyword>ICSI</keyword>
  <keyword>long agonist protocol</keyword>
  <keyword>TAC</keyword>
  <keyword>TOS</keyword>
  <keyword>OSI</keyword>
  <keyword>MDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

